Correlates of late-onset antipsychotic treatment resistance. (1st June 2022)

• Record Type: Journal Article
• Authors: Fonseca De Freitas, D.; Agbedjro, D.; Kadra-Scalzo, G.; Francis, E.; Ridler, I.; Pritchard, M.; Shetty, H.; Segev, A.; Casetta, C.; Smart, S.; Morris, A.; Downs, J.; Christensen, S.; Bak, N.; Kinon, B.; Stahl, D.; Hayes, R.; Maccabe, J.
• Is Part Of: European psychiatry. Volume 65:Supplement 1(2022)
• Page Start: S781
• Page End: S782
• Publication Date: 2022-06-01
• Subjects: secondary TRS -- refractory psychosis; Psychiatry -- Periodicals; Mental illness -- Periodicals; Electronic journals; 616.89
• DOI: 10.1192/j.eurpsy.2022.2018
• Languages: English
• ISSNs: 0924-9338

Abstract

Abstract : Introduction: There is emerging evidence of heterogeneity within treatment-resistance schizophrenia (TRS), with some people not responding to antipsychotic treatment from illness onset and a smaller group becoming treatment-resistant after an initial response period. It has been suggested that these groups have different aetiologies. Few studies have investigated socio-demographic and clinical differences between early and late onset of TRS. Objectives: This study aims to investigate socio-demographic and clinical correlates of late-onset of TRS. Methods: Using data from the electronic health records of the South London and Maudsley, we identified a cohort of people with TRS. Regression analyses were conducted to identify correlates of the length of treatment to TRS. Analysed predictors include gender, age, ethnicity, positive symptoms severity, problems with activities of daily living, psychiatric comorbidities, involuntary hospitalisation and treatment with long-acting injectable antipsychotics. Results: We observed a continuum of the length of treatment until TRS presentation. Having severe hallucinations and delusions at treatment start was associated shorter duration of treatment until the presentation of TRS. Conclusions: Our findings do not support a clear cut categorisation between early and late TRS, based on length of treatment until treatment resistance onset. More severe positive symptoms predict earlier onset of treatment resistance. Disclosure: DFdF, GKS, EF and IR have received research funding from Janssen and H. Lundbeck A/S. RDH and HS have received research funding from Roche, Pfizer, Janssen and Lundbeck. SES is employed on a grant held by Cardiff University from Takeda Pharmaceutical Comp